Omeros Corporation (OMER) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Omeros Corporation (OMER) has a cash flow conversion efficiency ratio of 0.084x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.47 Million) by net assets ($-220.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Omeros Corporation - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Omeros Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Omeros Corporation balance sheet liabilities for a breakdown of total debt and financial obligations.
Omeros Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Omeros Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
-0.026x |
|
Integra LifeSciences Holdings
NASDAQ:IART
|
0.039x |
|
GuangDong Rifeng Electric Cable Co Ltd
SHE:002953
|
0.025x |
|
Ottogi
KO:007310
|
0.057x |
|
Artis Real Estate Investment Trust
TO:AX-UN
|
0.040x |
|
Yijiahe Technology Co Ltd
SHG:603666
|
-0.030x |
|
Treasure ASA
OL:TRE
|
0.012x |
|
Itcen Co. Ltd
KQ:124500
|
0.210x |
Annual Cash Flow Conversion Efficiency for Omeros Corporation (2007–2024)
The table below shows the annual cash flow conversion efficiency of Omeros Corporation from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see OMER stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-182.61 Million | $-148.80 Million | 0.815x | +127.24% |
| 2023-12-31 | $-24.98 Million | $74.73 Million | -2.991x | -196.34% |
| 2022-12-31 | $85.68 Million | $-86.48 Million | -1.009x | +78.12% |
| 2021-12-31 | $23.78 Million | $-109.72 Million | -4.614x | -656.68% |
| 2020-12-31 | $-120.75 Million | $-100.09 Million | 0.829x | +50.42% |
| 2019-12-31 | $-109.02 Million | $-60.07 Million | 0.551x | +153.20% |
| 2018-12-31 | $100.16 Million | $-103.74 Million | -1.036x | -108.05% |
| 2017-12-31 | $-2.81 Million | $-36.23 Million | 12.874x | +836.02% |
| 2016-12-31 | $-37.45 Million | $-51.50 Million | 1.375x | -44.67% |
| 2015-12-31 | $-26.23 Million | $-65.21 Million | 2.486x | +82.66% |
| 2014-12-31 | $-42.65 Million | $-58.04 Million | 1.361x | -15.75% |
| 2013-12-31 | $-18.38 Million | $-29.70 Million | 1.615x | +903.15% |
| 2012-12-31 | $-214.58 Million | $-34.55 Million | 0.161x | -96.52% |
| 2011-12-31 | $-5.55 Million | $-25.67 Million | 4.622x | +752.34% |
| 2010-12-31 | $20.47 Million | $-14.50 Million | -0.708x | -60.65% |
| 2009-12-31 | $43.15 Million | $-19.03 Million | -0.441x | -304.36% |
| 2008-12-31 | $-91.17 Million | $-19.67 Million | 0.216x | +5.44% |
| 2007-12-31 | $-69.94 Million | $-14.31 Million | 0.205x | -- |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more